Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82,657 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Transradial versus transfemoral method of percutaneous coronary revascularization for unprotected left main coronary artery disease: comparison of procedural and late-term outcomes.
Yang YJ, Kandzari DE, Gao Z, Xu B, Chen JL, Qiao SB, Li JJ, Qin XW, Yao M, Wu YJ, Yuan JQ, Chen J, Liu HB, Dai J, Chen T, Wang Y, Li W, Gao RL. Yang YJ, et al. Among authors: li jj, li w. JACC Cardiovasc Interv. 2010 Oct;3(10):1035-42. doi: 10.1016/j.jcin.2010.09.003. JACC Cardiovasc Interv. 2010. PMID: 20965462 Free article.
A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
Xu B, Dou KF, Han YL, Lü SZ, Yang YJ, Huo Y, Wang LF, Chen YD, Wang HC, Li WM, Chen JY, Wang L, Wang Y, Ge JB, Li W, Gao RL. Xu B, et al. Among authors: li w, li wm. Chin Med J (Engl). 2011 Mar;124(6):811-6. Chin Med J (Engl). 2011. PMID: 21518585 Clinical Trial.
Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.
Xu B, Dou K, Yang Y, Lv S, Wang L, Wang H, Li Z, Wang L, Chen Y, Huo Y, Li W, Kirtane AJ, Gao R. Xu B, et al. Among authors: li z, li w. EuroIntervention. 2012 Nov 22;8(7):796-802. doi: 10.4244/EIJV8I7A122. EuroIntervention. 2012. PMID: 23171800 Free article. Clinical Trial.
Efficacy and safety of FIREHAWK® abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary lesions: nine-month angiographic and one-year clinical results from TARGET I trial long cohort.
Xu B, Gao RL, Zhang RY, Wang HC, Li ZQ, Yang YJ, Ma CS, Han YL, Lansky AJ, Huo Y, Li W, Leon MB. Xu B, et al. Among authors: li w, li zq. Chin Med J (Engl). 2013 Mar;126(6):1026-32. Chin Med J (Engl). 2013. PMID: 23506573
A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL, Xu B, Lansky AJ, Yang YJ, Ma CS, Han YL, Chen SL, Li H, Zhang RY, Fu GS, Yuan ZY, Jiang H, Huo Y, Li W, Zhang YJ, Leon MB; TARGET I Investigators. Gao RL, et al. Among authors: li w, li h. EuroIntervention. 2013 May 20;9(1):75-83. doi: 10.4244/EIJV9I1A12. EuroIntervention. 2013. PMID: 23685298 Free article. Clinical Trial.
82,657 results
You have reached the last available page of results. Please see the User Guide for more information.